TP508 (TFA)

TP508 TFA is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues[1][2].

O=C(NCC(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CCCCN)C(N2[C@@H](CCC2)C(N[C@@H](CC(O)=O)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N[C@@H](CS)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CO)C(NCC(NCC(N3[C@@H](CCC3)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C)N.FC(C(O)=O)(F)F

[1]Olszewska-Pazdrak B, et al. Nuclear Countermeasure Activity of TP508 Linked to Restoration of Endothelial Function and Acceleration of DNA Repair. Radiat Res. 2016 Aug;186(2):162-74.|[2]Olszewska-Pazdrak B, et al. Systemic administration of thrombin peptide TP508 enhances VEGF-stimulated angiogenesis and attenuates effects of chronic hypoxia. J Vasc Res. 2013;50(3):186-9|[3]Tsopanoglou NE, et al. On the mode of action of thrombin-induced angiogenesis: thrombin peptide, TP508, mediates effects in endothelial cells via alphavbeta3 integrin. Thromb Haemost. 2004 Oct;92(4):846-57.